ARAY

Business Context and Reporting Period

Company: Accuray Incorporated
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2009
Business Overview: Accuray designs, develops, and sells the CyberKnife system, an image-guided robotic radiosurgery system used to treat solid tumors anywhere in the body. The company operates globally with subsidiaries in Europe, Asia, and the Americas. As of December 31, 2009, 190 CyberKnife systems were installed at customer sites.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Total net revenue decreased slightly by 1% ($0.3 million) for the three months ended Dec 31, 2009, compared to the same period in 2008. For the six-month period, revenue decreased 5% ($5.6 million).
  • Product Revenue: Declined 14% (three months) and 16% (six months) due to fewer system installations and the phase-out of legacy "Platinum" service plan revenue recognition.
  • Service Revenue: Increased 49% (three months) and 35% (six months), driven by growth in the installed base under service plans.
• Gross Margin: Gross profit margin decreased from 51.0% to 45.3% (three months) and 51.0% to 44.1% (six months). This was primarily due to a higher mix of service revenue (which has lower margins than product revenue) and the sale of non-medical items with lower margins.
• Operating Expenses:
  • Selling & Marketing: Decreased 6% (three months) and 23% (six months) due to workforce alignment plans and reduced travel.
  • R&D: Decreased 12% (three months) and 12% (six months) due to lower compensation and consulting costs.
  • G&A: Increased 13% (three months) due to higher legal and accounting fees related to ongoing litigation, partially offset by lower compensation costs.
• Income Taxes: The company recorded a tax benefit of $0.7 million for the quarter and $0.6 million for the six months, primarily due to the carryback of alternative minimum tax losses under a federal law change enacted in November 2009.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management anticipates non-Platinum revenue will continue to grow while Platinum revenue decreases. Service revenue is expected to increase as the installed base grows. The company believes current cash resources are sufficient for at least the next 12 months.
• Unusual Items:
  • Investment Accounting: The company reclassified Auction-Rate Securities (ARS) from available-for-sale to trading securities due to a Rights Agreement with UBS. This resulted in the recognition of unrealized gains/losses in "Other income, net."
  • Inventory Write-down: A $2.2 million loss on write-down of inventories was recorded in the six months ended Dec 31, 2009.
• Risks and Contingencies:
  • Litigation: The company is subject to consolidated securities class action lawsuits and shareholder derivative lawsuits alleging false statements regarding operations. Additionally, a lawsuit was filed by Best Medical International alleging misappropriation of trade secrets. No liabilities have been recorded as losses are not considered probable or estimable.
  • Market Acceptance: Success depends on physician acceptance, third-party reimbursement rates (noting modest decreases in 2010 Medicare rates), and the ability to compete with traditional surgery and other radiation therapies.
  • Supply Chain: Reliance on single-source suppliers for critical components (e.g., robotic manipulator, magnetron) poses a risk to manufacturing timelines.
  • Regulatory: Future product upgrades may require new FDA 510(k) clearances or premarket approvals, which could delay sales.

Investor Verification Checklist

• Revenue Recognition Timing: Verify the impact of the "Platinum" legacy service plan phase-out on future revenue recognition, as revenue is deferred until upgrade obligations are met.
• Backlog Conversion: Assess the $325 million backlog and the risks associated with converting these orders into revenue, given the long sales cycle (up to 24 months) and potential for customer cancellations due to financing difficulties.
• Litigation Exposure: Monitor the status of the securities class action and derivative lawsuits, as well as the Best Medical trade secret claim, for potential financial impact.
• Reimbursement Rates: Track changes in Medicare and third-party payer reimbursement rates for CyberKnife procedures, as reductions could dampen customer demand.
• Investment Liquidity: Review the status of the $22.1 million in Auction-Rate Securities (ARS) and the associated Rights Agreement with UBS, noting the liquidity constraints and fair value adjustments.